SG11201408398UA - Compositions and methods for regulating car t cells - Google Patents
Compositions and methods for regulating car t cellsInfo
- Publication number
- SG11201408398UA SG11201408398UA SG11201408398UA SG11201408398UA SG11201408398UA SG 11201408398U A SG11201408398U A SG 11201408398UA SG 11201408398U A SG11201408398U A SG 11201408398UA SG 11201408398U A SG11201408398U A SG 11201408398UA SG 11201408398U A SG11201408398U A SG 11201408398UA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- cells
- methods
- regulating car
- regulating
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000001105 regulatory effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261671518P | 2012-07-13 | 2012-07-13 | |
PCT/US2013/050272 WO2014011987A1 (en) | 2012-07-13 | 2013-07-12 | Compositions and methods for regulating car t cells |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201408398UA true SG11201408398UA (en) | 2015-02-27 |
Family
ID=49916567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201408398UA SG11201408398UA (en) | 2012-07-13 | 2013-07-12 | Compositions and methods for regulating car t cells |
Country Status (14)
Country | Link |
---|---|
US (3) | US20150140019A1 (en) |
EP (1) | EP2872218A4 (en) |
JP (1) | JP2015525765A (en) |
KR (1) | KR20150030724A (en) |
CN (1) | CN104507537A (en) |
AU (1) | AU2013289970A1 (en) |
BR (1) | BR112015000310A2 (en) |
CA (1) | CA2878856A1 (en) |
EA (1) | EA201590207A1 (en) |
IL (1) | IL236679A0 (en) |
IN (1) | IN2014DN10889A (en) |
MX (1) | MX2015000428A (en) |
SG (1) | SG11201408398UA (en) |
WO (1) | WO2014011987A1 (en) |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3744736A1 (en) | 2013-02-20 | 2020-12-02 | Novartis AG | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
EP3626741A1 (en) | 2013-02-20 | 2020-03-25 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
EP2970426B1 (en) | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
TWI654206B (en) | 2013-03-16 | 2019-03-21 | 諾華公司 | Treatment of cancer with a humanized anti-CD19 chimeric antigen receptor |
WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
CA3225453A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
US10287354B2 (en) | 2013-12-20 | 2019-05-14 | Novartis Ag | Regulatable chimeric antigen receptor |
KR20230076867A (en) | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | Combination therapy with neoantigen vaccine |
EP3097117B1 (en) | 2014-01-21 | 2023-10-04 | Novartis Ag | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
HUE054588T2 (en) | 2014-04-07 | 2021-09-28 | Novartis Ag | Treatment of cancer using anti-cd19 chimeric antigen receptor |
CN112481283A (en) | 2014-07-21 | 2021-03-12 | 诺华股份有限公司 | Treatment of cancer using CD33 chimeric antigen receptor |
TWI750110B (en) | 2014-07-21 | 2021-12-21 | 瑞士商諾華公司 | Treatment of cancer using humanized anti- bcma chimeric antigen receptor |
AU2015292811B2 (en) | 2014-07-21 | 2019-12-19 | Novartis Ag | Treatment of cancer using a CLL-1 chimeric antigen receptor |
US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
MY189028A (en) | 2014-08-19 | 2022-01-20 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
AU2015317608B2 (en) | 2014-09-17 | 2021-03-11 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
CA2963935A1 (en) | 2014-10-08 | 2016-04-14 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
JP6898244B2 (en) * | 2014-11-06 | 2021-07-07 | ユニバーシティー オブ メリーランド,ボルティモア | Mutants of CD8α and T cell receptors and methods of using them in the regulation of immune cell responses |
EP3233095A2 (en) * | 2014-12-17 | 2017-10-25 | Cellectis | INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN |
WO2016100977A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Methods for profiling the t-cel- receptor repertoire |
US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
TW201631152A (en) | 2014-12-29 | 2016-09-01 | 諾華公司 | Methods of making chimeric antigen receptor - expressing cells |
US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
EP3250605A1 (en) | 2015-01-26 | 2017-12-06 | Cellectis | Anti-hsp70 specific chimeric antigen receptors (cars) for cancer immunotherapy |
US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
SI3280729T1 (en) | 2015-04-08 | 2022-09-30 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell |
ES2948133T3 (en) | 2015-04-17 | 2023-08-31 | Novartis Ag | Methods to improve the efficiency and expansion of cells expressing a chimeric antigen receptor |
MX2017014700A (en) | 2015-05-20 | 2018-08-15 | Broad Inst Inc | Shared neoantigens. |
AU2016279062A1 (en) | 2015-06-18 | 2019-03-28 | Omar O. Abudayyeh | Novel CRISPR enzymes and systems |
AU2016283102B2 (en) * | 2015-06-25 | 2021-03-11 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (CARs), compositions and methods of use thereof |
EP3325504A1 (en) | 2015-07-21 | 2018-05-30 | Novartis AG | Methods for improving the efficacy and expansion of immune cells |
EP3331913A1 (en) | 2015-08-07 | 2018-06-13 | Novartis AG | Treatment of cancer using chimeric cd3 receptor proteins |
WO2017030370A1 (en) * | 2015-08-17 | 2017-02-23 | 서울대학교산학협력단 | Chimeric antibody receptor to which anti-cotinine antibody is linked, and use thereof |
EP4218777A3 (en) | 2015-08-28 | 2023-08-23 | The Trustees of the University of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
US11890301B2 (en) | 2015-08-28 | 2024-02-06 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
CN108780084B (en) | 2015-09-03 | 2022-07-22 | 诺华股份有限公司 | Biomarkers predictive of cytokine release syndrome |
WO2017069958A2 (en) | 2015-10-09 | 2017-04-27 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
WO2017075478A2 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures |
AU2016355178B9 (en) | 2015-11-19 | 2019-05-30 | Massachusetts Institute Of Technology | Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity |
EP3393504A1 (en) | 2015-12-22 | 2018-10-31 | Novartis AG | Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy |
EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
WO2017184590A1 (en) | 2016-04-18 | 2017-10-26 | The Broad Institute Inc. | Improved hla epitope prediction |
US11630103B2 (en) | 2016-08-17 | 2023-04-18 | The Broad Institute, Inc. | Product and methods useful for modulating and evaluating immune responses |
WO2018049025A2 (en) | 2016-09-07 | 2018-03-15 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses |
WO2018067991A1 (en) | 2016-10-07 | 2018-04-12 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
TW202340473A (en) | 2016-10-07 | 2023-10-16 | 瑞士商諾華公司 | Treatment of cancer using chimeric antigen receptors |
WO2018073394A1 (en) * | 2016-10-19 | 2018-04-26 | Cellectis | Cell death inducing chimeric antigen receptors |
WO2018140391A1 (en) | 2017-01-24 | 2018-08-02 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
WO2018140725A1 (en) | 2017-01-26 | 2018-08-02 | Novartis Ag | Cd28 compositions and methods for chimeric antigen receptor therapy |
CN116693695A (en) | 2017-02-12 | 2023-09-05 | 百欧恩泰美国公司 | HLA-based methods and compositions and uses thereof |
WO2018160622A1 (en) * | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
MX2019011272A (en) | 2017-03-22 | 2019-10-24 | Novartis Ag | Compositions and methods for immunooncology. |
WO2018183908A1 (en) | 2017-03-31 | 2018-10-04 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
WO2018183921A1 (en) | 2017-04-01 | 2018-10-04 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
US20200071773A1 (en) | 2017-04-12 | 2020-03-05 | Massachusetts Eye And Ear Infirmary | Tumor signature for metastasis, compositions of matter methods of use thereof |
EP3612629A1 (en) | 2017-04-18 | 2020-02-26 | The Broad Institute, Inc. | Compositions for detecting secretion and methods of use |
US11897953B2 (en) | 2017-06-14 | 2024-02-13 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
US20220233588A1 (en) | 2017-06-30 | 2022-07-28 | Cellectis | Cellular immunotherapy for repetitive administration |
CA3073848A1 (en) | 2017-09-21 | 2019-03-28 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
EP3697436A1 (en) | 2017-10-18 | 2020-08-26 | Novartis AG | Compositions and methods for selective protein degradation |
US11732257B2 (en) | 2017-10-23 | 2023-08-22 | Massachusetts Institute Of Technology | Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries |
EP3710039A4 (en) | 2017-11-13 | 2021-08-04 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
US11793867B2 (en) | 2017-12-18 | 2023-10-24 | Biontech Us Inc. | Neoantigens and uses thereof |
US11994512B2 (en) | 2018-01-04 | 2024-05-28 | Massachusetts Institute Of Technology | Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity |
CN112055595A (en) | 2018-01-22 | 2020-12-08 | 恩多塞特公司 | Methods of use of CAR T cells |
US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
WO2019232542A2 (en) | 2018-06-01 | 2019-12-05 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
KR20210020932A (en) | 2018-06-13 | 2021-02-24 | 노파르티스 아게 | BCMA chimeric antigen receptor and uses thereof |
WO2020068304A2 (en) | 2018-08-20 | 2020-04-02 | The Broad Institute, Inc. | Inhibitors of rna-guided nuclease target binding and uses thereof |
US20210355522A1 (en) | 2018-08-20 | 2021-11-18 | The Broad Institute, Inc. | Inhibitors of rna-guided nuclease activity and uses thereof |
US20210324357A1 (en) | 2018-08-20 | 2021-10-21 | The Brigham And Women's Hospital, Inc. | Degradation domain modifications for spatio-temporal control of rna-guided nucleases |
WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
WO2020081730A2 (en) | 2018-10-16 | 2020-04-23 | Massachusetts Institute Of Technology | Methods and compositions for modulating microenvironment |
WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
US20220154282A1 (en) | 2019-03-12 | 2022-05-19 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
EP3942023A1 (en) | 2019-03-18 | 2022-01-26 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
US20220235340A1 (en) | 2019-05-20 | 2022-07-28 | The Broad Institute, Inc. | Novel crispr-cas systems and uses thereof |
US20220226464A1 (en) | 2019-05-28 | 2022-07-21 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
WO2021030627A1 (en) | 2019-08-13 | 2021-02-18 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
WO2021041922A1 (en) | 2019-08-30 | 2021-03-04 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
JP2022547570A (en) | 2019-09-12 | 2022-11-14 | ザ・ブロード・インスティテュート・インコーポレイテッド | Engineered adeno-associated virus capsid |
US11981922B2 (en) | 2019-10-03 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
US11844800B2 (en) | 2019-10-30 | 2023-12-19 | Massachusetts Institute Of Technology | Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia |
IL292924A (en) | 2019-11-26 | 2022-07-01 | Novartis Ag | Cd19 and cd22 chimeric antigen receptors and uses thereof |
US11865168B2 (en) | 2019-12-30 | 2024-01-09 | Massachusetts Institute Of Technology | Compositions and methods for treating bacterial infections |
EP4375292A1 (en) * | 2021-07-21 | 2024-05-29 | Korea Research Institute of Bioscience and Biotechnology | Novel chimeric antigen receptor and immune cells expressing same |
WO2024077256A1 (en) | 2022-10-07 | 2024-04-11 | The General Hospital Corporation | Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins |
WO2024124044A1 (en) | 2022-12-07 | 2024-06-13 | The Brigham And Women’S Hospital, Inc. | Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4792447A (en) * | 1981-07-23 | 1988-12-20 | Board Of Regents, The University Of Texas System | Anti-immunoglobulin toxin conjugates useful in the treatment of B cell tumors |
US5977316A (en) * | 1995-01-17 | 1999-11-02 | The Board Of Trustees Of The University Of Kentucky | Monoclonal antibody 1A7 and related polypeptides |
ATE475428T1 (en) * | 2000-03-29 | 2010-08-15 | Univ Ohio State Res Found | METHOD FOR BLOCKING THE DESTRUCTION OF TISSUE USING AUTOREACTIVE T CELLS |
US7514537B2 (en) * | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
SG10201404273QA (en) * | 2003-12-23 | 2014-10-30 | Genentech Inc | Novel anti-il 13 antibodies and uses thereof |
JP2009506790A (en) * | 2005-09-07 | 2009-02-19 | メディミューン,エルエルシー | EPH receptor antibody conjugated to toxin |
US7968687B2 (en) * | 2007-10-19 | 2011-06-28 | Seattle Genetics, Inc. | CD19 binding agents and uses thereof |
DE102010039018B4 (en) * | 2010-08-06 | 2013-02-28 | Technische Universität Dresden | Anti-La antibodies and their use for immuno-targeting |
KR20230133410A (en) * | 2010-12-09 | 2023-09-19 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Use of chimeric antigen receptor-modified t cells to treat cancer |
EP3693017A1 (en) * | 2010-12-14 | 2020-08-12 | University of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer |
-
2013
- 2013-07-12 WO PCT/US2013/050272 patent/WO2014011987A1/en active Application Filing
- 2013-07-12 SG SG11201408398UA patent/SG11201408398UA/en unknown
- 2013-07-12 KR KR20157000921A patent/KR20150030724A/en not_active Application Discontinuation
- 2013-07-12 EA EA201590207A patent/EA201590207A1/en unknown
- 2013-07-12 JP JP2015521840A patent/JP2015525765A/en active Pending
- 2013-07-12 IN IN10889DEN2014 patent/IN2014DN10889A/en unknown
- 2013-07-12 MX MX2015000428A patent/MX2015000428A/en unknown
- 2013-07-12 CN CN201380037380.XA patent/CN104507537A/en active Pending
- 2013-07-12 AU AU2013289970A patent/AU2013289970A1/en not_active Abandoned
- 2013-07-12 US US14/408,851 patent/US20150140019A1/en not_active Abandoned
- 2013-07-12 EP EP13816421.5A patent/EP2872218A4/en not_active Withdrawn
- 2013-07-12 CA CA2878856A patent/CA2878856A1/en not_active Abandoned
- 2013-07-12 BR BR112015000310A patent/BR112015000310A2/en not_active Application Discontinuation
-
2015
- 2015-01-12 IL IL236679A patent/IL236679A0/en unknown
-
2018
- 2018-12-11 US US16/216,460 patent/US20190367610A1/en not_active Abandoned
-
2022
- 2022-05-03 US US17/735,624 patent/US20230034117A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230034117A1 (en) | 2023-02-02 |
US20150140019A1 (en) | 2015-05-21 |
IN2014DN10889A (en) | 2015-09-11 |
EA201590207A1 (en) | 2015-05-29 |
US20190367610A1 (en) | 2019-12-05 |
KR20150030724A (en) | 2015-03-20 |
MX2015000428A (en) | 2015-03-12 |
CN104507537A (en) | 2015-04-08 |
EP2872218A1 (en) | 2015-05-20 |
CA2878856A1 (en) | 2014-01-16 |
AU2013289970A1 (en) | 2015-01-22 |
IL236679A0 (en) | 2015-02-26 |
WO2014011987A1 (en) | 2014-01-16 |
BR112015000310A2 (en) | 2017-06-27 |
JP2015525765A (en) | 2015-09-07 |
EP2872218A4 (en) | 2016-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL236679A0 (en) | Compositions and methods for regulating car t cells | |
IL272539B (en) | Compositions and methods for immunotherapy | |
HK1251246A1 (en) | Methods and compositions for desulfurization of compositions | |
ZA201502884B (en) | Compositions and methods for modulating cell signaling | |
SG10201705024PA (en) | Methods and compositions for separating or enriching cells | |
EP2892523A4 (en) | Methods and compositions for regenerating hair cells and/or supporting cells | |
EP2922861A4 (en) | Biomarker compositions and methods | |
EP2823306A4 (en) | Biomarker compositions and methods | |
EP2850184A4 (en) | Compositions and methods for modulating gene expression | |
EP2850183A4 (en) | Compositions and methods for modulating gene expression | |
EP2862226A4 (en) | Electrochemical slurry compositions and methods for preparing the same | |
HUE061931T2 (en) | Methods and compositions for natural killer cells | |
EP2850189A4 (en) | Compositions and methods for modulating gene expression | |
SG11201500799YA (en) | Hla g-modified cells and methods | |
HK1205942A1 (en) | Compositions, methods, and kits for regulating energy metabolism | |
IL237916A0 (en) | Compositions and methods for producing glycoproteins | |
ZA201407412B (en) | Method and compositions for preventing stem cell disruption and aggregation | |
HK1212733A1 (en) | Compositions and methods for vitamin-rich fermentates | |
IL239484A0 (en) | Agents for eliminating tumour-initiating cells | |
EP2852662A4 (en) | Herpesvirus compositions and related methods | |
GB201220058D0 (en) | Cell differentiation | |
IL239529B (en) | Compositions and methods for creating altered and improved cells and organisms | |
HK1210436A1 (en) | Novel cell compositions and methods | |
IL239426A0 (en) | Biomarker methods and compositions | |
EP2931293A4 (en) | Compositions and methods for regulating erythropoiesis |